Serum Institute of India, the world's biggest vaccine maker, is hopeful of launching Covovax - developed in partnership with American vaccine developer Novavax - by June, its CEO Adar Poonawalla said today. The US-based pharma firm's Covid jab was found to be 89.3 per cent effective in a UK trial.
The Pune-based Serum Institute has already applied for local trials for the vaccine candidate in India. "Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!" Adar Poonawalla tweeted this afternoon," Mr Poonawalla's tweet read.
Earlier this month, India began the world's largest inoculation drive after the drug regulator DCGI cleared two vaccines - the SII's Covishield and Hyderabad-based pharma firm Bharat Biotech's Covaxin.
Covishield has been developed in partnership with the Oxford University and British-Swedish firm AstraZeneca.
India is the fastest country in the world to vaccinate three million people, the government said in a series of tweets on Friday, drawing comparison with other nations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.